Samsung BioLogics wins potential $148m contract at new plant

By Dan Stanton contact

- Last updated on GMT


Related tags: Samsung biologics, South korea

The manufacturing contract is the first of what Samsung BioLogics expects to be a number of long-term partnerships at its recently completed 180,000L facility.

Late last year​, South Korean contract development and manufacturing organisation (CDMO) Samsung BioLogics announced construction at its third and largest plant at its Songdo, Incheon site was complete.

Validation is ongoing and expected to be completed by the end of the year, but despite this the firm announced this week it has entered into its first manufacturing contract at the plant.

Details of the client has not been divulged, but Samsung BioLogics described the customer as a “fast growing company.”​ If the product moves successfully into commercial production, Samusng BioLogics could net up to $148m (€120m).

The third plant adds 180,000L of stainless steel bioreactor capacity, effectively doubling the total capacity across Samsung BioLogics other two plants.

A spokesperson from the firm told Biopharma-Reporter this deal is just the start of what is expected to be high and fast deployment at the new plant.

“We are now discussing with multiple biopharma companies for long-term partnerships, so the capacity [utilisation rate] will be absolutely getting bigger.”

While having three plants and a total of 362,000L of capacity, Samsung BioLogics said last year it is assessing building a fourth facility, potentially outside South Korea.

“Considering the growing needs of our clients for tax reasons and geographic risk management, there is a lot of demand to build a plant out of Korea,”​​ CEO TH Kim told delegates at the CPhI Preconnect Congress in Frankfurt, Germany in October​.

“We are seriously considering building a future plant out of Korea, hopefully in Europe or America, near to our clients.”​​

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more